

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:)	
)	Chapter 11
Apple Tree Life Sciences, Inc., <i>et al.</i> , ¹)	
)	Case No. 25-12177 (LSS)
Debtors.)	(Jointly Administered)

**STATEMENT OF FINANCIAL AFFAIRS FOR
ATP LIFE SCIENCE VENTURES, L.P. CASE NO. 25-12178**

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Therapeutics Incorporated (8493). The location of the Debtors' service Avenue, Suite 2800, New York, NY 10169.



251217726013000000000011

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

Apple Tree Life Sciences, Inc., *et al.*,¹

Debtors.

Chapter 11

Case No. 25-12177 (LSS)

(Jointly Administered)

**GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY,
AND DISCLAIMERS REGARDING THE DEBTORS' SCHEDULES OF ASSETS
AND LIABILITIES AND STATEMENTS OF FINANCIAL AFFAIRS**

General

Apple Tree Life Sciences, Inc. ("ATLS"), and its debtor affiliates, as debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the "Debtors"), are filing their respective *Schedules of Assets and Liabilities* (each, a "Schedule," and collectively, the "Schedules") and *Statements of Financial Affairs* (each, a "Statement," and collectively with the Schedules, the "Schedules and Statements") with the United States Bankruptcy Court for District of Delaware (the "Bankruptcy Court") pursuant to section 521 of title 11 of the United States Code (the "Bankruptcy Code"), rule 1007 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), and Rule 1007-1 of the Local Rules of the United States Bankruptcy Court for the District of Delaware (the "Local Rules").

These global notes and statements of limitations, methodology and disclaimers regarding the Debtors' Schedules and Statements (the "Global Notes") pertain to, are incorporated by reference in, and comprise an integral part of, all of the Schedules and Statements, and should be referred to, and referenced in connection with, any review of the Schedules and Statements.²

The Schedules and Statements are unaudited and reflect the Debtors' reasonable efforts to report certain financial information of each Debtor on a stand-alone, unconsolidated basis. These Schedules and Statements neither purport to represent financial statements prepared in

¹ The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

² These Global Notes supplement, and are in addition to, any specific notes contained in each Debtor's Schedules or Statements. The fact that the Debtors prepared these Global Notes with respect to any of the individual Debtor's Schedules and Statement and not to those of another should not be interpreted as a decision by the Debtors to exclude the applicability of such Global Note to any of the Debtors' other Schedules and Statements, as appropriate.

accordance with Generally Accepted Accounting Principles in the United States (“GAAP”), nor are they intended to be fully reconciled with the financial statements of each Debtor.

In preparing the Schedules and Statements, the Debtors relied on financial data derived from their books and records that were available at the time of such preparation. Although the Debtors have made commercially reasonable efforts to ensure the accuracy and completeness of the Schedules and Statements, subsequent information or discovery may result in material changes to the Schedules and Statements. As a result, inadvertent errors or omissions may exist. Accordingly, the Debtors and their directors, managers, officers, agents, attorneys and financial advisors do not guarantee or warrant the accuracy or completeness of the data that is provided herein, and shall not be liable for any loss or injury arising out of or caused in whole or in part by the acts, errors, or omissions, whether negligent or otherwise, in procuring, compiling, collecting, interpreting, reporting, communicating, or delivering the information contained herein or the Schedules and Statements. In no event shall the Debtors or their directors, managers, officers, agents, attorneys and financial advisors be liable to any third party for any direct, indirect, incidental, consequential, or special damages (including, but not limited to, damages arising from the disallowance of a potential claim against the Debtors or damages to business reputation, lost business, or lost profits), whether foreseeable or not and however caused, even if the Debtors or their directors, managers, officers, agents, attorneys, and financial advisors are advised of the possibility of such damages.

The Schedules and Statements have been signed by Perry M. Mandarino, the Debtors’ Chief Restructuring Officer. Mr. Mandarino is an authorized signatory for each of the Debtors. In reviewing and signing the Schedules and Statements, Mr. Mandarino relied upon the efforts, statements, advice, and representations of personnel of the Debtors and the Debtors’ advisors and other professionals. Given the scale of the Debtors’ businesses, Mr. Mandarino has not (and practically could not have) personally verified the accuracy of each statement and representation in the Schedules and Statements, including, but not limited to, statements and representations concerning amounts owed to creditors, classification of such amounts, and creditor addresses.

Subsequent receipt of information or an audit may result in material changes in financial data requiring amendment of the Schedules and Statements. Accordingly, the Schedules and Statements remain subject to further review and verification by the Debtors. The Debtors reserve their right to amend the Schedules and Statements from time-to-time as may be necessary or appropriate; provided, that the Debtors, their agents, and their advisors expressly do not undertake any obligation to update, modify, revise, or recategorize the information provided herein or to notify any third party should the information be updated, modified, revised, or recategorized, except to the extent required by applicable law.

The Schedules, Statements, and Global Notes should not be relied upon by any persons for information relating to current or future financial conditions, events, or performance of any of the Debtors.

Global Notes and Overview of Methodology

1. **Description of the Cases.** The Debtors commenced these voluntary cases under chapter 11 of the Bankruptcy Code on December 9 and 15, 2025 and January 1 and 15, 2026 (collectively, the “Petition Dates,” and each, a “Petition Date”). The Debtors are authorized to operate their businesses and manage their properties as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. The Debtors’ chapter 11 cases are being jointly administered for procedural purposes only pursuant to Bankruptcy Rule 1015(b). *See* Docket Nos. 69, 178 & 200. On January 20, 2026, the United States Trustee for the District of Delaware (the “U.S. Trustee”) appointed an Official Committee of Unsecured Creditors pursuant to section 1102(a)(1) of the Bankruptcy Code (the “UCC”) [Docket No. 194]. Notwithstanding the joint administration of the Debtors’ cases for procedural purposes, each Debtor has filed, or will file, its own Schedules and Statements.

2. **Global Notes Control.** Disclosure of information in one or more Schedules, one or more Statements, or one or more exhibits or attachments to the Schedules or Statements, even if incorrectly placed, shall be deemed to be disclosed in the correct Schedules, Statements, exhibits, or attachments. In the event that the Schedules or Statements differ from any of the Global Notes, the Global Notes shall control.

3. **Reservation of Rights.** Commercially reasonable efforts have been made to prepare and file complete and accurate Schedules and Statements; however, as noted above, inadvertent errors or omissions may exist. The Debtors reserve all rights to amend and supplement the Schedules and Statements as may be necessary or appropriate but do not undertake any obligation to do so, except as required by applicable law. Nothing contained in the Schedules, Statements, or Global Notes shall constitute a waiver of rights with respect to these chapter 11 cases, including, but not limited to, any rights or claims of the Debtors against any third party or issues involving substantive consolidation, defenses, statutory or equitable subordination, and/or causes of action arising under the provisions of chapter 5 of the Bankruptcy Code or any other relevant applicable bankruptcy or non-bankruptcy laws to recover assets or avoid transfers. Any specific reservation of rights contained elsewhere in the Global Notes does not limit in any respect the general reservation of rights contained in this paragraph.
 - a. **No Admission.** Nothing contained in the Schedules and Statements is intended as, or should be construed as, an admission or stipulation of the validity of any claim against any Debtors, any assertion made therein or herein, or a waiver of any of the Debtors’ rights to dispute any claim or assert any cause of action or defense against any party.

 - b. **Claims Listing and Descriptions.** The listing of a claim does not constitute an admission of liability by the Debtors, and the Debtors reserve the right to amend the Schedules and Statements accordingly. Any failure to designate a claim listed on the Schedules and Statements as “disputed,” “contingent,” or “unliquidated” does not constitute an admission by the Debtors that such amount is not “disputed,” “contingent,” or “unliquidated.” The Debtors reserve the right to dispute and to assert

- setoff rights, counterclaims, and defenses to any claim reflected on their Schedules and Statements on any grounds, including, but not limited to, amount, liability, priority, status, and classification, and to otherwise subsequently designate any claim as “disputed,” “contingent,” or “unliquidated.”
- c. Recharacterization.** The Debtors have made reasonable efforts to correctly characterize, classify, categorize, and designate the claims, assets, executory contracts, unexpired leases, and other items reported in the Schedules and Statements. Nevertheless, due to the complexity of the Debtors’ businesses, the Debtors may not have accurately characterized, classified, categorized, or designated certain items and/or may have omitted certain items. Accordingly, the Debtors reserve all of their rights to recharacterize, reclassify, recategorize, or redesignate items reported in the Schedules and Statements at a later time as necessary or appropriate, including, without limitation, whether contracts or leases listed herein were deemed executory or unexpired as of the Petition Date and remain executory and unexpired post-petition.
- d. Classifications.** The listing of a claim (i) on Schedule D as “secured,” (ii) on Schedule E/F as either “priority,” or “unsecured priority,” or (iii) listing a contract or lease on Schedule G as “executory” or “unexpired” does not constitute an admission by the Debtors of the legal rights of the claimant or contract counterparty, or a waiver of the Debtors’ rights to recharacterize or reclassify such claim or contract pursuant to a schedule amendment, claim objection or otherwise. Moreover, although the Debtors may have scheduled claims of various creditors as secured claims for informational purposes, no current valuation of the Debtors’ assets in which such creditors may have a security interest has been undertaken. Except as provided in an order of the Court, the Debtors reserve all rights to dispute and challenge the secured nature or amount of any such creditor’s claims or the characterization of the structure of any transaction, or any document or instrument related to such creditor’s claim.
- e. Estimates and Assumptions.** To prepare these Schedules and Statements and report information on a legal entity basis, the Debtors were required to make certain reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities, the amount of contingent assets and contingent liabilities as of the Petition Date. Actual results could differ from such estimates. The Debtors reserve all rights to amend the reported amounts of assets and liabilities to reflect changes in those estimates or assumptions.
- f. Causes of Action.** Despite reasonable efforts, the Debtors may not have identified and/or set forth all of their causes of action (filed or potential) against third parties as assets in their Schedules and Statements, including, without limitation, avoidance actions arising under chapter 5 of the Bankruptcy Code and actions under other relevant bankruptcy and non-bankruptcy laws to recover assets. The Debtors reserve all rights with respect to any claim, controversy, demand, right, action, suit, obligation, liability, debt, account, defense, offset, power, privilege, license, lien, indemnity, guaranty, interest, damage, remedy, cause of action, proceeding, agreement, or franchise of any kind or character whatsoever, whether known or unknown, foreseen or unforeseen, existing or hereinafter arising, contingent or non-

contingent, liquidated or unliquidated, secured or unsecured, assertable, directly or derivatively, matured or unmatured, suspected or unsuspected, whether arising before, on, or after the Petition Date, in contract, in tort, at law, in equity, or otherwise. Causes of action also include: (a) all rights of setoff, counterclaim, or recoupment and claims under contracts or for breaches of duties imposed by law or in equity; (b) any claim based on or relating to, or in any manner arising from, in whole or in part, tort, breach of contract, breach of fiduciary duty, violation of local, state, federal, or foreign law, or breach of any duty imposed by law or in equity, including, without limitation, securities laws, negligence, and gross negligence; (c) the right to object to or otherwise contest claims or interests; (d) claims pursuant to sections 362 or chapter 5 of the Bankruptcy Code; (e) such claims and defenses as fraud, mistake, duress, and usury, and any other defenses set forth in section 558 of the Bankruptcy Code; and (f) any avoidance actions arising under chapter 5 of the Bankruptcy Code or under similar local, state, federal, or foreign statutes and common law, including, without limitation, fraudulent transfer laws, and neither the Global Notes nor the Schedules and Statements shall be deemed a waiver of any such claims, causes of action, or avoidance actions, or in any way prejudice or impair the assertion of such claims or causes of action.

g. Intellectual Property Rights. Exclusion of certain intellectual property on the Statements and Schedules shall not be construed to be an admission that such intellectual property rights have been abandoned, have been terminated, or otherwise have expired by their terms, or have been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. Conversely, inclusion of certain intellectual property on the Statements and Schedules shall not be construed to be an admission that such intellectual property rights have not been abandoned, have not been terminated, or otherwise have not expired by their terms, or have not been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. The Debtors have made every effort to attribute intellectual property to the rightful Debtor owner, however, in some instances, intellectual property owned by one Debtor may, in fact, be owned by another. Accordingly, the Debtors reserve all of their rights with respect to the legal status of any and all intellectual property rights.

h. Insiders. The Debtors have attempted to include all payments made on or within twelve months before the Petition Date to any individual (and their relatives) or entity who, in the Debtors' good faith belief, may be deemed an "insider" as set forth in section 101(31) of the Bankruptcy Code. As to each Debtor, an individual or entity is designated as an "insider" for the purposes of the Schedules and Statements if such individual or entity, based on the totality of the circumstances, has at least a controlling interest in, or exercises sufficient authority over, the Debtor so as to dictate corporate policy and the disposition of corporate assets.

The listing or omission of a party as an "insider" for the purposes of the Schedules and Statements is for informational purposes and is not intended to be nor should be construed as an admission that those parties are insiders for purposes of section 101(31) of the Bankruptcy Code. Information regarding the individuals or entities listed as insiders in the Schedules and Statements may not be used for: (a) the

purposes of determining (i) control of the Debtors; (ii) the extent to which any individual or entity exercised management responsibilities or functions; (iii) corporate decision-making authority over the Debtors; or (iv) whether such individual or entity (or the Debtors) could successfully argue that they are not an insider under applicable law, including the Bankruptcy Code and federal securities laws, or with respect to any theories of liability or (b) any other purpose. Furthermore, certain of the individuals or entities identified as insiders may not have been insiders for the entirety of the twelve-month period before the Petition Date. The Debtors reserve all rights with respect thereto.

4. **Methodology**

- a. **Basis of Presentation.** These Schedules and Statements neither purport to represent financial statements prepared in accordance with GAAP nor are they intended to fully reconcile to the financial statements prepared by the Debtors. Information contained in the Schedules and Statements has been derived from the Debtors' books and records and historical financial statements.

The Debtors attempted to attribute the assets and liabilities, certain required financial information, and various cash disbursements to the proper Debtor entity. However, due to limitations within Debtors' accounting systems, it is possible that not all assets, liabilities or amounts of cash disbursements have been recorded with the correct legal entity on the Schedules and Statements. Accordingly, the Debtors reserve all rights to supplement and/or amend the Schedules and Statements in this regard.

Given, among other things, the uncertainty surrounding the collection, ownership, and valuation of certain assets and the amount and nature of certain liabilities, a Debtor may report more assets than liabilities. Such report shall not constitute an admission that such Debtor was solvent on the Petition Date or at any time prior to or after the Petition Date. Likewise, a Debtor reporting more liabilities than assets shall not constitute an admission that such Debtor was insolvent on the Petition Date or at any time prior to or after the Petition Date. For the avoidance of doubt, nothing contained in the Schedules and Statements is indicative of the Debtors' enterprise value. The Schedules and Statements contain unaudited information that is subject to further review and potential adjustment.

- b. **Reporting Date.** Unless otherwise noted, the Schedules and Statements generally reflect the Debtors' books and records as of the Petition Date.
- c. **Confidentiality or Sensitive Information.** There may be instances in which certain information in the Schedules and Statements intentionally has been redacted due to concerns about the privacy of the Debtors' employees and vendors (*e.g.*, home addresses). The alterations will be limited to only what is necessary to protect the Debtor or the applicable third party. The Debtors may also be authorized or required to redact certain information from the public record pursuant to orders of the Court authorizing the Debtors to redact, seal, or otherwise protect such information from public disclosure.

- d. **Duplication.** Certain of the Debtors' assets, liabilities, and prepetition payments may properly be disclosed in response to multiple parts of the Statements and Schedules. To the extent these disclosures would be duplicative, the Debtors have determined to only list such assets, liabilities, and prepetition payments once.
- e. **Net Book Value of Assets.** In many instances, current market valuations are not maintained by or readily available to the Debtors. It would be prohibitively expensive, unduly burdensome, and an inefficient use of estate resources for the Debtors to obtain current market valuations for all assets. As such, unless otherwise indicated, net book values are as of the Petition Date. When necessary, the Debtors have indicated that the value of certain assets is "Unknown" or "Undetermined." The description of an amount as "unknown" or "undetermined" is not intended to reflect upon the materiality of such amount. Amounts ultimately realized may vary materially from net book value (or other value so ascribed). Accordingly, the Debtors reserve all rights to amend, supplement, and adjust the asset values set forth in the Schedules and Statements. Assets that have been fully depreciated or that were expensed for accounting purposes either do not appear in these Schedules and Statements or are listed with a zero-dollar value, as such assets have no net book value. The omission of an asset from the Schedules and Statements does not constitute a representation regarding the ownership of such asset, and any such omission does not constitute a waiver of any rights of the Debtors with respect to such asset. Nothing in the Debtors' Schedules and Statements shall be, or shall be deemed to be, an admission that any Debtor was solvent or insolvent as of the Petition Date or any time prior to the Petition Date.
- f. **Currency.** All amounts shown in the Schedules and Statements are in U.S. Dollars, unless otherwise indicated.
- g. **Payment of Prepetition Claims Pursuant to Payment Orders.** Following the Petition Date, the Court entered various orders authorizing the Debtors to, among other things, pay certain prepetition claims, including without limitation: insurance obligations; employee wages, salaries, and related items (including, but not limited to, employee benefit programs and contractor wage obligations); and other obligations (collectively, the "Payment Orders"). Accordingly, certain of these liabilities may have been, or will be, satisfied in accordance with the Payment Orders. Where the Schedules list creditors and set forth the Debtor's scheduled amount of such claims, such scheduled amounts reflect amounts owed as of the Petition Date. The Debtors reserve the right to amend and/or supplement the Schedules and Statements to reflect payments made pursuant to an order of the Court.
- h. **Other Paid Claims.** To the extent the Debtors have reached any post-petition settlement with a vendor or other creditor, the terms of such settlement will prevail, supersede amounts listed in the Schedules and Statements, and shall be enforceable by all parties, subject to any necessary Court approval. To the extent the Debtors pay any of the claims listed in the Schedules and Statements pursuant to any orders entered by the Court, the Debtors reserve all rights to amend and supplement the Schedules and Statements and take other action, such as filing claims objections, as is

necessary and appropriate to avoid overpayment or duplicate payment for such liabilities.

- i. **Leases.** Nothing in the Schedules and Statements is, or shall be construed to be, an admission as to the determination of the legal status of any lease (including whether any lease is a true lease, a financing arrangement, or a real property interest), and the Debtors reserve all rights with respect to such issues.
- j. **Liens.** The inventories, property, and equipment listed in the Statements and Schedules are presented without consideration of any asserted mechanics', materialmen, or similar liens that may attach (or have attached) to such inventories, property, and equipment, and the Debtors reserve all of their rights with respect to such liens (if any).
- k. **Allocation of Liabilities.** The Debtors, in consultation with their advisors, have sought to allocate liabilities between the prepetition and post-petition periods based on the information and research that was conducted in connection with the preparation of the Schedules and Statements. As additional information becomes available and further research is conducted, the allocation of liabilities between prepetition and post-petition periods may change. The Debtors reserve the right to amend and/or supplement the Schedules and Statements as they deem appropriate in this regard.
- l. **Totals.** All totals that are included in the Schedules and Statements represent totals of all the known amounts included in the Schedules and Statements and exclude items identified as "unknown" or "undetermined." If there are unknown or undetermined amounts, the actual totals may be materially different from the listed totals. The description of an amount as "unknown" or "undetermined" is not intended to reflect upon the materiality of such amount.
- m. **Unliquidated Claim Amounts.** Claim amounts that could not be readily quantified by the Debtors are scheduled as "unliquidated."
- n. **Credits and Adjustments.** The claims of individual creditors for, among other things, goods, products, services, and taxes are listed as the amounts entered on the Debtors' books and records and may either (i) not reflect credits, allowances, or other adjustments due from such creditors to the Debtors or (ii) be net of accrued credits, allowances, rebates, trade debits, or other adjustments that are actually owed by a creditor to the Debtors on a post-petition basis on account of such credits, allowances, or other adjustments earned from prepetition payments and post-petition payments, if applicable. The Debtors reserve all of their rights with regard to such credits, allowances, and other adjustments, including but not limited to, the right to assert claims objections and/or setoffs with respect to the same.

- o. Claims of Third-Party Related Entities.** While the Debtors have made every effort to properly classify each claim listed in the Schedules as being either disputed or undisputed, liquidated or unliquidated, and contingent or noncontingent, the Debtors have not been able to fully reconcile all payments made to certain third parties and their related entities on account of the Debtors' obligations thereto. Therefore, to the extent that the Debtors have classified their estimate of claims of a creditor as disputed, all claims of such creditor's affiliates listed in the Schedules and Statements shall similarly be considered as disputed, whether or not they are designated as such.

Notes Specific to Schedules of Assets and Liabilities

Schedule A/B: Assets

Part 1 – Cash and Cash Equivalents

- (a) **Question 3 – Checking, Savings, Money Market, or Financial Brokerage Accounts.** Further details with respect to the Debtors' cash management system and bank accounts are also provided in the *Final Order (I) Authorizing the Debtors to (A) Continue to Operate Their Cash Management System and (B) Honor Certain Pre-Petition Obligations Related Thereto, and (II) Granting Related Relief* [Docket No. 189] and the *Order (I) Directing Joint Administration of Additional Chapter 11 Cases and (II) Extending Certain Relief Granted to the Original Debtors* [Docket No. 200].

Part 2 – Deposits and Prepayments

- (a) **Question 8 – Prepayments.** In the ordinary course of business, Debtor ATP Life Science Ventures, L.P. advances a bi-annual management fee (the "**Management Fee**") to Debtor Apple Tree Life Sciences, Inc. to pay for operating costs and management expenses. The Management Fee is not identified on the Schedules and Statements because payment of any further Management Fees is subject to further orders of the Court. The Debtors may have inadvertently omitted deposits and conversely may have reported deposits that are no longer outstanding. The Debtors reserve their rights, but are not required, to amend the Schedules and Statements if deposits are incorrectly identified. Certain prepayments may be reflected on an amortized basis to the extent recorded in the Debtors' books and records as such.

Part 4 – Investments

- (a) **Question 15 – Non-Publicly Traded Stock and Interests in Incorporated and Unincorporated Businesses, Including any Interest in an LLC, Partnership, or Joint Venture.** Schedule A/B 15 includes Debtor ATP Life Science Ventures, L.P.'s ownership interest in the debtor and non-debtor portfolio companies. The value of the Debtor's interest listed therein is based on the Debtor's audited financial statements as of December 31, 2024 and may not be reflective of current values as to which the Debtors reserve all rights.

Part 11 – All Other Assets

- (a) Question 73 – Interests in Insurance Policies or Annuities. A list of the Debtor’s insurance policies can be found in the *Debtors’ Motion for Entry of an Order (I) Authorizing the Debtors to (A) Pay Their Obligations Under Prepetition Insurance Policies, (B) Continue to Pay Certain Brokerage Fees, (C) Renew, Supplement, Modify or Purchase Insurance Coverage, and (II) Granting Related relief* [Docket No. 106] and the *Debtors’ Motion for an Order (I) Directing Joint Administration of Additional Chapter 11 Case and (II) Extending Certain Relief Granted to the Original Debtors* [Docket No. 162]. Accordingly, the Debtors have not duplicated such information in Schedule A/B 73.
- (b) Question 75 – Other Contingent and Unliquidated Claims or Causes of Action. Certain Debtors are party to two matters before the Delaware Court of Chancery from which they stand to receive judgment payouts. Debtor ATP Life Science Ventures, L.P. is a potential beneficiary of an approximately \$370 million Chancery Court damages award and judgment in *Shareholder Representative Services LLC v. Alexion Pharmaceuticals, Inc.*, No. 2020-1069-MTZ. However, this is not yet a final judgment and as such has been listed in the Schedules and Statements as a contingent and undetermined claim or cause of action. Additionally, the Debtors were awarded \$97 million in specific performance in *ATP III GP, Ltd. v. Rigmora Biotech Investor One LP*, No. 2025-0607. The money transferred to the Debtors on account of that judgment is not readily available to them as described in the *Order Authorizing the Debtors to Open New Segregated Bank Account* [Docket No. 79], and therefore is not listed in the Schedules and Statements.
- (c) Question 77 – Other Property of Any Kind not Already Listed. The value of the intercompany balances listed on Schedule A/B 77 are listed as of the Petition Date.

Schedule D: Creditors Who Have Claims Secured by Property

Except as otherwise agreed pursuant to a stipulation or order entered by the Bankruptcy Court, the Debtors reserve their rights to dispute or challenge the validity, perfection, or immunity from avoidance of any lien purported to be granted or perfected in any specific asset to a secured creditor listed on Schedule D of any Debtor. Moreover, although the Debtors may have scheduled claims of various creditors as secured claims, the Debtors reserve all rights to dispute or challenge the secured nature of any such creditor’s claim or the characterization of the structure of any such transaction or any document or instrument (including, without limitation, any intercompany agreement) related to such creditor’s claim. Further, the listing of a claim as secured is not an admission as to the validity of any lien. The descriptions provided in Schedule D are intended only to be a summary. Reference to the applicable lease agreements and related documents is necessary for a complete description of the collateral and the nature, extent, and priority of any liens. Nothing in these Global Notes or the Schedules and Statements shall be deemed a modification or interpretation of the terms of such agreements.

Schedule E/F: Creditors Who Have Unsecured Claims

The liabilities identified in Schedule E/F, Part 2, are derived from the Debtors' books and records. The Debtors made reasonable attempts to set forth their unsecured obligations, although the actual amount of claims against the Debtors may vary from those liabilities represented on Schedule E/F, Part 2. The listed liabilities may not reflect the correct amount of any unsecured creditor's allowed claims or the correct amount of all unsecured claims. The amounts listed on schedule E/F may not reflect any right of setoff or recoupment, and the Debtors reserve any such setoff or recoupment rights. Some of the scheduled liabilities may be unknown, contingent and/or unliquidated at this time. In such cases, the amounts may be listed as "Undetermined." Accordingly, the Schedules and the Statements may not equal the aggregate value of the Debtors' total liabilities as noted on any previously issued financial statements.

In addition to nonpriority unsecured claims by third-party claimants, intercompany payables between and among the Debtors and non-Debtor affiliates are also reported on Schedule E/F, Part 2.

Schedule G: Unexpired Leases and Executory Contracts

The contracts, agreements and leases listed on Schedule G may have expired or may have been modified, amended or supplemented from time to time by various amendments, restatements, waivers, estoppels, certificates, letters, memoranda or other documents, instruments and agreements that may not be listed on Schedule G, despite the Debtor's use of reasonable efforts to identify such documents. Certain of the executory contracts and unexpired leases listed on Schedule G may contain certain renewal options, guarantees of payment, options to purchase, rights of first refusal, and other miscellaneous rights, which are not set forth separately on Schedule G. In addition, the Debtor may have entered into various other types of agreements in the ordinary course of business, such as subordination, non disturbance and attornment agreements, supplemental agreements, amendments/letter agreements, title agreements and confidentiality agreements. Such documents may not be set forth on Schedule G. Certain of the executory contracts may not have been memorialized and may be subject to dispute. Certain of the executory contracts or unexpired leases listed in Schedule G may include one or more ancillary documents, including but not limited to any underlying assignment and assumption agreements, amendments, supplements, full and partial assignments, renewals and partial releases. Executory contracts that are oral in nature, if any, have not been included on Schedule G. To the extent the Bankruptcy Court determines a particular contract is executory, the Debtor will amend Schedule G to add that contract, as necessary or appropriate.

Omission of a contract or agreement from Schedule G does not constitute an admission that such omitted contract or agreement is not an executory contract or unexpired lease. The Debtor's rights under the Bankruptcy Code with respect to any such omitted contracts or agreements are not impaired by the omission.

Notes Specific to Statements of Financial Affairs

Part 1, Question 1 – Income. Revenue has been presented from January 1, 2025, through the Petition Date.

Part 2, Question 3 – Payments or Transfers to Certain Creditors. The Debtors have responded in detailed format by listing the payments by vendor. The response does not include any transfers to the Debtors' bankruptcy professionals for services related to these chapter 11 cases (such transfers are disclosed under Part 6, Question 11).

Part 2, Question 4 – Payments or Other Transfers of Property Made Within 1 Year Before the Petition Date That Benefited Any Insider. Prior to the Petition Date, in the ordinary course of business, the Debtors engaged in intercompany transactions among the Management Debtors and Portfolio Companies (the "Intercompany Funding"). Intercompany Funding payments made within one (1) year before the Petition Date are reported on Statement 4. The listing of any amounts with respect to such Intercompany Funding is not, and should not be construed as, an admission of the characterization of such balances as debt, equity, or otherwise.

Part 6, Question 11 – Payments Related to Bankruptcy. The Debtors have used reasonable efforts to identify payments for services of any entities who provided consultation concerning debt counseling or restructuring services, relief under the Bankruptcy Code or preparation of a petition in bankruptcy within one year immediately before the Petition Date, which are identified in the Debtors' response to Part 6, Question 11 of the Statements. Additional information regarding the Debtors' retention of professional service firms is more fully described in the individual retention applications for those firms and any related orders. *See* Docket Nos. 22, 131, 132, 133, 134, 137, & 148.

Part 13, Question 25 – Other Businesses in Which the Debtor Has or Has Had an Interest. The Debtors have used reasonable efforts to identify the Employer Identification Numbers for the entities listed on Statement 25. However, the Debtors no longer hold an interest in certain entities disclosed on Statement 25 and could not reasonably ascertain such entities' Employer Identification Numbers.

Part 13, Question 28 – Officers, Directors, General Partners, Members in Control, Controlling Shareholders, or Other People in Control of the Debtor as of the Petition Date. The ownership interests disclosed on Statement 28 are reported on a fully diluted basis as of September 30, 2025.

Part 13, Question 30 – Payments, Distributions, or Withdrawals Credited or Given to Insiders. Any such payments were identified in Statement 4 so as to not duplicate disclosures.

Fill in this information to identify the case:

Debtor Name: In re : ATP Life Science Ventures, L.P.
 United States Bankruptcy Court for the: District Of Delaware
 Case number (if known): 25-12178 (LSS)

Check if this is an amended filing

Official Form 207

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy 04/25

The debtor must answer every question. If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor's name and case number (if known).

Part 1: Income

1. Gross revenue from business

None

Identify the beginning and ending dates of the debtor's fiscal year, which may be a calendar year	Sources of revenue Check all that apply	Gross revenue (before deductions and exclusions)
From the beginning of the fiscal year to filing date: From _____ to Filing date MM / DD / YYYY	<input type="checkbox"/> Operating a business <input type="checkbox"/> Other _____	\$ _____
For prior year: From _____ to _____ MM / DD / YYYY MM / DD / YYYY	<input type="checkbox"/> Operating a business <input type="checkbox"/> Other _____	\$ _____
For the year before that: From _____ to _____ MM / DD / YYYY MM / DD / YYYY	<input type="checkbox"/> Operating a business <input type="checkbox"/> Other _____	\$ _____

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

2. Non-business revenue

Include revenue regardless of whether that revenue is taxable. Non-business income may include interest, dividends, money collected from lawsuits, and royalties. List each source and the gross revenue for each separately. Do not include revenue listed in line 1.

None

		Description of sources of revenue	Gross revenue from each source (before deductions and exclusions)
From the beginning of the fiscal year to filing date:	From _____ to Filing date MM / DD / YYYY	_____	\$ _____
For prior year:	From _____ to _____ MM / DD / YYYY MM / DD / YYYY	_____	\$ _____
For the year before that:	From _____ to _____ MM / DD / YYYY MM / DD / YYYY	_____	\$ _____

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 2: List Certain Transfers Made Before Filing for Bankruptcy

3. Certain payments or transfers to creditors within 90 days before filing this case

List payments or transfers-including expense reimbursements-to any creditor, other than regular employee compensation, within 90 days before filing this case unless the aggregate value of all property transferred to that creditor is less than \$8,575 . (This amount may be adjusted on 4/01/28 and every 3 years after that with respect to cases filed on or after the date of adjustment.)

None

Creditor's name and address	Dates	Total amount or value	Reasons for payment or transfer Check all that apply
3.1 See SOFA 3 Attachment Creditor's Name Street City State ZIP Code Country		\$	<input type="checkbox"/> Secured debt <input type="checkbox"/> Unsecured loan repayments <input type="checkbox"/> Suppliers or vendors <input type="checkbox"/> Services <input type="checkbox"/> Other

4. Payments or other transfers of property made within 1 year before filing this case that benefited any insider

List payments or transfers, including expense reimbursements, made within 1 year before filing this case on debts owed to an insider or guaranteed or cosigned by an insider unless the aggregate value of all property transferred to or for the benefit of the insider is less than \$8,575. (This amount may be adjusted on 4/01/28 and every 3 years after that with respect to cases filed on or after the date of adjustment.) Do not include any payments listed in line 3. Insiders include officers, directors, and anyone in control of a corporate debtor and their relatives; general partners of a partnership debtor and their relatives; affiliates of the debtor and insiders of such affiliates; and any managing agent of the debtor. 11 U.S.C. § 101(31).

None

Insider's Name and Address	Dates	Total amount or value	Reason for payment or transfer
4.1 See SOFA 4 Attachment Insider's Name Street City State ZIP Code Country Relationship to Debtor		\$	

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

5. Repossessions, foreclosures, and returns

List all property of the debtor that was obtained by a creditor within 1 year before filing this case, including property repossessed by a creditor, sold at a foreclosure sale, transferred by a deed in lieu of foreclosure, or returned to the seller. Do not include property listed in line 6.

None

Creditor's Name and Address	Description of the Property	Date	Value of property
5.1 Creditor's Name			\$
Street			
City State ZIP Code			
Country			

6. Setoffs

List any creditor, including a bank or financial institution, that within 90 days before filing this case set off or otherwise took anything from an account of the debtor without permission or refused to make a payment at the debtor's direction from an account of the debtor because the debtor owed a debt.

None

Creditor's Name and Address	Description of the action creditor took	Date action was taken	Amount
6.1 Creditor's Name			\$
Street			
City State ZIP Code	Last 4 digits of account number: XXXX-		
Country			

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 4: Certain Gifts and Charitable Contributions

9. List all gifts or charitable contributions the debtor gave to a recipient within 2 years before filing this case unless the aggregate value of the gifts to that recipient is less than \$1,000

None

Recipient's name and address	Description of the gifts or contributions	Dates given	Value
9.1 Creditor's Name Street City State ZIP Code Country Recipient's relationship to debtor			\$

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 5: Certain Losses

10. All losses from fire, theft, or other casualty within 1 year before filing this case.

None

Description of the property lost and how the loss occurred	Amount of payments received for the loss If you have received payments to cover the loss, for example, from insurance, government compensation, or tort liability, list the total received. List unpaid claims on Official Form 106A/B (Schedule A/B: Assets – Real and Personal Property).	Date of loss	Value of property lost
10.1			\$

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 6: Certain Payments or Transfers

11. Payments related to bankruptcy

List any payments of money or other transfers of property made by the debtor or person acting on behalf of the debtor within 1 year before the filing of this case to another person or entity, including attorneys, that the debtor consulted about debt consolidation or restructuring, seeking bankruptcy relief, or filing a bankruptcy case.

None

Who was paid or who received the transfer?	If not money, describe any property transferred	Dates	Total amount or value
11.1 See SOFA 11 Attachment			\$

Address

Street

City

State

ZIP Code

Country

Email or website address

Who made the payment, if not debtor?

12. Self-settled trusts of which the debtor is a beneficiary

List any payments or transfers of property made by the debtor or a person acting on behalf of the debtor within 10 years before the filing of this case to a self-settled trust or similar device.

Do not include transfers already listed on this statement.

None

Name of trust or device	Describe any property transferred	Dates transfers were made	Total amount or value
12.1			\$

Trustee

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

13. Transfers not already listed on this statement

List any transfers of money or other property - by sale, trade, or any other means - made by the debtor or a person acting on behalf of the debtor within 2 years before the filing of this case to another person, other than property transferred in the ordinary course of business or financial affairs. Include both outright transfers and transfers made as security. Do not include gifts or transfers previously listed on this statement.

None

Who received transfer?	Description of property transferred or payments received or debts paid in exchange	Date transfer was made	Total amount or value
13.1			\$

Address

Street

City State ZIP Code

Country

Relationship to Debtor

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 7: Previous Locations

14. Previous addresses

List all previous addresses used by the debtor within 3 years before filing this case and the dates the addresses were used.

Does not apply

Address	Dates of occupancy	
14.1 _____	From _____	To _____
Street		

City	State	ZIP Code
Country		

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 8: Health Care Bankruptcies

15. Health Care bankruptcies

Is the debtor primarily engaged in offering services and facilities for:
 — diagnosing or treating injury, deformity, or disease, or
 — providing any surgical, psychiatric, drug treatment, or obstetric care?

- No. Go to Part 9.
- Yes. Fill in the information below.

Facility Name and Address	Nature of the business operation, including type of services the debtor provides	If debtor provides meals and housing, number of patients in debtor's care
15.1 Facility Name		
Street	Location where patient records are maintained (if different from facility address). If electronic, identify any service provider.	How are records kept?
City State ZIP Code		Check all that apply: <input type="checkbox"/> Electronically <input type="checkbox"/> Paper
Country		

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name _____

Part 9: Personally Identifiable Information

16. Does the debtor collect and retain personally identifiable information of customers?

- No.
- Yes. State the nature of the information collected and retained. _____
 Does the debtor have a privacy policy about that information?
 No
 Yes

17. Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit?

- No. Go to Part 10.
- Yes. Does the debtor serve as plan administrator?
 No. Go to Part 10.
 Yes. Fill in below:

Name of plan	Employer identification number of the plan
17.1 _____	EIN: _____

- Has the plan been terminated?
- No
 - Yes

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 10: Certain Financial Accounts, Safe Deposit Boxes, and Storage Units

18. Closed financial accounts

Within 1 year before filing this case, were any financial accounts or instruments held in the debtor's name, or for the debtor's benefit, closed, sold, moved, or transferred? Include checking, savings, money market, or other financial accounts; certificates of deposit; and shares in banks, credit unions, brokerage houses, cooperatives, associations, and other financial institutions.

None

Financial institution name and address	Last 4 digits of account number	Type of account	Date account was closed, sold, moved, or transferred	Last balance before closing or transfer
18.1 Name Street City State ZIP Code Country	XXXX-	<input type="checkbox"/> Checking <input type="checkbox"/> Savings <input type="checkbox"/> Money market <input type="checkbox"/> Brokerage <input type="checkbox"/> Other		\$

19. Safe deposit boxes

List any safe deposit box or other depository for securities, cash, or other valuables the debtor now has or did have within 1 year before filing this case.

None

Depository institution name and address	Names of anyone with access to it	Description of the contents	Does debtor still have it?
19.1 Name Street City State ZIP Code Country			<input type="checkbox"/> No <input type="checkbox"/> Yes

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

20. Off-premises storage

List any property kept in storage units or warehouses within 1 year before filing this case. Do not include facilities that are in a part of a building in which the debtor does business.

None

Facility name and address	Names of anyone with access to it	Description of the contents	Does debtor still have it?
20.1			<input type="checkbox"/> No
Name			
Street			<input type="checkbox"/> Yes
City	State	ZIP Code	Address
Country			

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 11: Property the Debtor Holds or Controls That the Debtor Does Not Own

21. Property held for another

List any property that the debtor holds or controls that another entity owns. Include any property borrowed from, being stored for, or held in trust. Do not list leased or rented property.

None

	Owner's name and address	Location of the property	Description of the property	Value
21.1	Name			\$
	Street			
	City	State	ZIP Code	
	Country			

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 12: Details About Environmental Information

For the purpose of Part 12, the following definitions apply:

- *Environmental law* means any statute or governmental regulation that concerns pollution, contamination, or hazardous material, regardless of the medium affected (air, land, water, or any other medium).
- *Site* means any location, facility, or property, including disposal sites, that the debtor now owns, operates, or utilizes or that the debtor formerly owned, operated, or utilized.
- *Hazardous material* means anything that an environmental law defines as hazardous or toxic, or describes as a pollutant, contaminant, or a similarly harmful substance.

Report all notices, releases, and proceedings known, regardless of when they occurred.

22. Has the debtor been a party in any judicial or administrative proceeding under any environmental law? Include settlements and orders.

- No
- Yes. Provide details below.

Case title	Court or agency name and address	Nature of the case	Status of case
22.1	Name Street		<input type="checkbox"/> Pending <input type="checkbox"/> On appeal <input type="checkbox"/> Concluded
Case Number	City State ZIP Code		
	Country		

23. Has any governmental unit otherwise notified the debtor that the debtor may be liable or potentially liable under or in violation of an environmental law?

- No
- Yes. Provide details below.

Site name and address	Governmental unit name and address	Environmental law, if known	Date of notice
23.1 Name Street	Name Street		
City State ZIP Code	City State ZIP Code		
Country	Country		

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

24. Has the debtor notified any governmental unit of any release of hazardous material?

No

Yes. Provide details below.

Site name and address	Governmental unit name and address	Environmental law, if known	Date of notice
24.1			
Name	Name		
Street	Street		
City	City	State ZIP Code	State ZIP Code
Country	Country		

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

Part 13: Details About the Debtor's Business or Connections to Any Business

25. Other businesses in which the debtor has or has had an interest

List any business for which the debtor was an owner, partner, member, or otherwise a person in control within 6 years before filing this case. Include this information even if already listed in the Schedules.

None

Business name and address	Describe the nature of the business	Employer Identification number Do not include Social Security number or ITIN.
25.1 See SOFA 25 Attachment		EIN:
Name		Dates business existed
Street		From _____ To _____
City State ZIP Code		
Country		

26. Books, records, and financial statements

26a. List all accountants and bookkeepers who maintained the debtor's books and records within 2 years before filing this case.

None

Name and Address	Dates of service
26a.1 Apple Tree Life Sciences, Inc	From 10/2012 To Present
Name	
230 Park Avenue	
Street	
Suite 2800	
New York NY 10169	
City State ZIP Code	
Country	

26b. List all firms or individuals who have audited, compiled, or reviewed debtor's books of account and records or prepared a financial statement within 2 years before filing this case.

None

Name and Address	Dates of service
26b.1 Grant Thornton LLP	From 10/2012 To Present
Name	
757 3rd Avenue #9	
Street	
New York NY 10017-2013	
City State ZIP Code	
Country	

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

26c. List all firms or individuals who were in possession of the debtor's books of account and records when this case is filed.

None

Name and address	If any books of account and records are unavailable, explain why
------------------	--

26c.1 Apple Tree Life Sciences, Inc

Name

230 Park Avenue

Street

Suite 2800

New York

NY

10169

City

State

ZIP Code

Country

26d. List all financial institutions, creditors, and other parties, including mercantile and trade agencies, to whom the debtor issued a financial statement within 2 years before filing this case.

None

Name and address

26d.1

Name

Street

City

State

ZIP Code

Country

27. Inventories

Have any inventories of the debtor's property been taken within 2 years before filing this case?

No

Yes. Give the details about the two most recent inventories.

Name of the person who supervised the taking of the inventory	Date of Inventory	The dollar amount and basis (cost, market, or other basis) of each inventory
		\$ _____

Name and address of the person who has possession of inventory records
--

27.1

Name

Street

City

State

ZIP Code

Country

Debtor: ATP Life Science Ventures, L.P.

Case number (if known): 25-12178

Name

28. List the debtor's officers, directors, managing members, general partners, members in control, controlling shareholders, or other people in control of the debtor at the time of the filing of this case.

Name	Address	Position and Nature of any interest	% of interest, if any
28.1 See SOFA 28 Attachment			

29. Within 1 year before the filing of this case, did the debtor have officers, directors, managing members, general partners, members in control of the debtor, or shareholders in control of the debtor who no longer hold these positions?

- No
- Yes. Identify below.

Name	Address	Position and Nature of any interest	Period during which position or interest was held
29.1			From _____ To _____

30. Payments, distributions, or withdrawals credited or given to insiders

Within 1 year before filing this case, did the debtor provide an insider with value in any form, including salary, other compensation, draws, bonuses, loans, credits on loans, stock redemptions, and options exercised?

- No
- Yes. Identify below.

Name and address of recipient	Amount of money or description and value of property	Dates	Reason for providing the value
30.1 See SOFA Question 4			
Name _____			
Street _____			

City _____ State _____ ZIP Code _____			
Country _____			
Relationship to debtor _____			

31. Within 6 years before filing this case, has the debtor been a member of any consolidated group for tax purposes?

- No
- Yes. Identify below.

Name of the parent corporation	Employer Identification number of the parent corporation
31.1 _____	EIN: _____

32. Within 6 years before filing this case, has the debtor as an employer been responsible for contributing to a pension fund?

- No
- Yes. Identify below.

Name of the pension fund	Employer Identification number of the pension fund
32.1 _____	EIN: _____

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both.

18 U.S.C. §§ 152, 1341, 1519, and 3571.

I have examined the information in this *Statement of Financial Affairs* and any attachments and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 01/30/2026
MM / DD / YYYY

x / s / Perry M. Mandarino _____

Printed name Perry M. Mandarino

Signature of individual signing on behalf of the debtor

Position or relationship to debtor Chief Restructuring Officer

Are additional pages to *Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy (Official Form 207)* attached?

No

Yes

In re: ATP Life Science Ventures, L.P.**Case No. 25-12178**

SOFA 3 Attachment

Certain payments or transfers to creditors within 90 days before filing this case

Creditor Name & Address	Payment Date	Reason for Payment	Amount Paid
Analysis Group 111 Huntington Avenue, 14th Floor Boston, MA 02199	11/07/2025	Services	\$35,684.50
		SUBTOTAL	\$35,684.50
Cornerstone Research 699 Boylston Street Boston, MA 02116	11/07/2025	Services	\$90,843.00
	11/26/2025	Services	\$6,607.50
		SUBTOTAL	\$97,450.50
Patricia Gupta 675 Scenic Rim Drive Henderson, NV 89052	11/07/2025	Services	\$24,106.25
		SUBTOTAL	\$24,106.25
Quality Executive Partners, Inc. 200 N Washington Street, Suite 320910 Alexandria, VA 22320-0910	10/24/2025	Services	\$112,602.59
		SUBTOTAL	\$112,602.59
Quinn Emanuel Urquhart & Sullivan, LLP 865 S Figueroa Street, 10th Floor Los Angeles, CA 90017	11/03/2025	Services	\$789,546.92
	11/21/2025	Services	\$5,095,605.84
	12/05/2025	Services	\$11,911.75
	12/08/2025	Services	\$987,405.07
	12/09/2025	Services	\$1,554,789.68
		SUBTOTAL	\$8,439,259.26
Ross Aronstam & Moritz 1313 North Market Street, Suite 1001 Wilmington, DE 19801	12/5/2025	Services	\$9,219.10
		SUBTOTAL	\$9,219.10
Walkers (Cayman) LLP 190 Elgin Avenue George Town, Grand Cayman KY1-9001 Cayman Islands	10/30/2025	Services	\$259,596.61
	11/05/2025	Services	\$164,594.60
	11/20/2025	Services	\$28,155.05
	12/09/2025	Services	\$83,738.65
		SUBTOTAL	\$536,084.91
Watchell, Lipton, Rosen & Katz 51 West 52nd Street New York, NY 10019	12/01/2025	Services	\$251,000.00
		SUBTOTAL	\$251,000.00

In re: ATP Life Science Ventures, L.P.

Case No. 25-12178

SOFA 4 Attachment

Payments or other transfers of property made within 1 year before filing this case that benefited any insider

Creditor Name & Address	Payment Date	Reason for Payment	Relationship to Debtor	Amount Paid
Aethon Therapeutics, Inc. 30-02 48th Avenue Suite 280 Long Island City, NY 11101	8/11/2025	Intercompany Funding	Portfolio Company	\$2,000,000.00
			SUBTOTAL	\$2,000,000.00
Apertor Pharmaceuticals, Inc. 651 Gateway Blvd. Suite 1600 South San Francisco, CA 04080	1/10/2025	Intercompany Funding	Portfolio Company	\$4,000,000.00
	6/11/2025	Intercompany Funding	Portfolio Company	\$137,000.00
	6/17/2025	Intercompany Funding	Portfolio Company	\$43,623.63
	6/27/2025	Intercompany Funding	Portfolio Company	\$88,331.95
	6/30/2025	Intercompany Funding	Portfolio Company	\$15,671.85
	7/10/2025	Intercompany Funding	Portfolio Company	\$407,000.00
	7/23/2025	Intercompany Funding	Portfolio Company	\$165,000.00
	9/4/2025	Intercompany Funding	Portfolio Company	\$42,410.00
	9/10/2025	Intercompany Funding	Portfolio Company	\$110,775.50
	10/3/2025	Intercompany Funding	Portfolio Company	\$11,602.50
	10/3/2025	Intercompany Funding	Portfolio Company	\$20,908.37
	10/10/2025	Intercompany Funding	Portfolio Company	\$30,000.00
	10/28/2025	Intercompany Funding	Portfolio Company	\$49,100.00
	11/3/2025	Intercompany Funding	Portfolio Company	\$4,066.50
	11/12/2025	Intercompany Funding	Portfolio Company	\$35,000.00
	11/19/2025	Intercompany Funding	Portfolio Company	\$6,035.00
	11/25/2025	Intercompany Funding	Portfolio Company	\$45,000.00
	12/9/2025	Intercompany Funding	Portfolio Company	\$40,000.00
			SUBTOTAL	\$5,251,525.30
Apple Tree Life Sciences 230 Park Avenue, Suite 2800 New York, NY 10169	12/9/2025	Partnership Expenses	Affiliate	\$1,286,304.92
			SUBTOTAL	\$1,286,304.92
Apple Tree Venture Management, LLC 230 Park Avenue, Suite 2800 New York, NY 10169	1/2/2025	Management Fee	Affiliate	\$3,000,000.00
			SUBTOTAL	\$3,000,000.00
Ascidian Therapeutics, Inc. 80 Guest Street 4th Floor Boston, MA 02135	8/11/2025	Intercompany Funding	Portfolio Company	\$6,000,000.00
			SUBTOTAL	\$6,000,000.00
Aulos Bioscience, Inc. 700 Larkspur Landing Circle Suite 108 Larkspur, CA 94939	1/24/2025	Intercompany Funding	Portfolio Company	\$5,000,000.00
			SUBTOTAL	\$5,000,000.00
Deep Apple Therapeutics, Inc. 651 Gateway Blvd. Suite 1600 South San Francisco, CA 04080	1/24/2025	Intercompany Funding	Portfolio Company	\$6,000,000.00
	4/30/2025	Intercompany Funding	Portfolio Company	\$6,000,000.00
			SUBTOTAL	\$12,000,000.00
Evercrisp Therapeutics, Inc. 651 Gateway Blvd, Suite 1600 South San Francisco, CA 94080	2/7/2025	Intercompany Funding	Portfolio Company	\$4,000,000.00

In re: ATP Life Science Ventures, L.P.

Case No. 25-12178

SOFA 4 Attachment

Payments or other transfers of property made within 1 year before filing this case that benefited any insider

Creditor Name & Address	Payment Date	Reason for Payment	Relationship to Debtor	Amount Paid
Evercrisp Therapeutics, Inc. (Continued)	7/1/2025	Intercompany Funding	Portfolio Company	\$400,000.00
	7/14/2025	Intercompany Funding	Portfolio Company	\$100,000.00
	7/30/2025	Intercompany Funding	Portfolio Company	\$157,000.00
	8/14/2025	Intercompany Funding	Portfolio Company	\$120,000.00
	8/27/2025	Intercompany Funding	Portfolio Company	\$130,000.00
	9/10/2025	Intercompany Funding	Portfolio Company	\$19,316.25
	9/12/2025	Intercompany Funding	Portfolio Company	\$65,000.00
	9/26/2025	Intercompany Funding	Portfolio Company	\$68,000.00
	10/1/2025	Intercompany Funding	Portfolio Company	\$15,000.00
	10/3/2025	Intercompany Funding	Portfolio Company	\$17,532.50
	10/10/2025	Intercompany Funding	Portfolio Company	\$45,000.00
	10/14/2025	Intercompany Funding	Portfolio Company	\$25,000.00
	10/28/2025	Intercompany Funding	Portfolio Company	\$85,000.00
	11/5/2025	Intercompany Funding	Portfolio Company	\$8,000.00
	11/6/2025	Intercompany Funding	Portfolio Company	\$5,000.00
	11/12/2025	Intercompany Funding	Portfolio Company	\$55,000.00
	11/19/2025	Intercompany Funding	Portfolio Company	\$5,930.00
	11/25/2025	Intercompany Funding	Portfolio Company	\$40,000.00
12/1/2025	Intercompany Funding	Portfolio Company	\$25,000.00	
12/9/2025	Intercompany Funding	Portfolio Company	\$55,000.00	
			SUBTOTAL	\$5,440,778.75
Initial Therapeutics, Inc. 651 Gateway Blvd, Suite 1600 South San Francisco, CA 94080	1/10/2025	Intercompany Funding	Portfolio Company	\$4,000,000.00
	4/10/2025	Intercompany Funding	Portfolio Company	\$500,000.00
	4/18/2025	Intercompany Funding	Portfolio Company	\$1,500,000.00
	7/10/2025	Intercompany Funding	Portfolio Company	\$230,000.00
	7/30/2025	Intercompany Funding	Portfolio Company	\$155,000.00
	8/14/2025	Intercompany Funding	Portfolio Company	\$575,000.00
	8/22/2025	Intercompany Funding	Portfolio Company	\$77,000.00
	9/11/2025	Intercompany Funding	Portfolio Company	\$31,000.00
	9/24/2025	Intercompany Funding	Portfolio Company	\$100,000.00
	9/26/2025	Intercompany Funding	Portfolio Company	\$40,000.00
	10/3/2025	Intercompany Funding	Portfolio Company	\$13,326.25
	10/24/2025	Intercompany Funding	Portfolio Company	\$3,050.44
	10/28/2025	Intercompany Funding	Portfolio Company	\$25,000.00
	11/3/2025	Intercompany Funding	Portfolio Company	\$20,552.50
	11/19/2025	Intercompany Funding	Portfolio Company	\$7,563.75
	12/3/2025	Intercompany Funding	Portfolio Company	\$45,000.00
12/9/2025	Intercompany Funding	Portfolio Company	\$16,000.00	
			SUBTOTAL	\$7,338,492.94
Les Pommes 230 Park Avenue, Suite 2800 New York, NY 10169	4/10/2025	Tax Distribution	Director	\$203,152.10
			SUBTOTAL	\$203,152.10
Marlinspike Therapeutics, Inc. 245 Main Street 12th floor Cambridge, MA 02142	3/27/2025	Intercompany Funding	Portfolio Company	\$1,000,000.00
	7/2/2025	Intercompany Funding	Portfolio Company	\$12,500.00
	7/10/2025	Intercompany Funding	Portfolio Company	\$225,000.00
	7/30/2025	Intercompany Funding	Portfolio Company	\$165,000.00
	8/22/2025	Intercompany Funding	Portfolio Company	\$100,000.00
	9/10/2025	Intercompany Funding	Portfolio Company	\$28,626.25

In re: ATP Life Science Ventures, L.P.

Case No. 25-12178

SOFA 4 Attachment

Payments or other transfers of property made within 1 year before filing this case that benefited any insider

Creditor Name & Address	Payment Date	Reason for Payment	Relationship to Debtor	Amount Paid
Marlinspike Therapeutics, Inc. (Continued)	10/3/2025	Intercompany Funding	Portfolio Company	\$18,651.25
	10/28/2025	Intercompany Funding	Portfolio Company	\$35,000.00
	11/12/2025	Intercompany Funding	Portfolio Company	\$34,000.00
	11/19/2025	Intercompany Funding	Portfolio Company	\$3,726.68
	12/9/2025	Intercompany Funding	Portfolio Company	\$15,000.00
				SUBTOTAL
Nereid Therapeutics, Inc. 245 Main Street 12th floor Cambridge, MA 02142	1/10/2025	Intercompany Funding	Portfolio Company	\$6,400,000.00
	6/17/2025	Intercompany Funding	Portfolio Company	\$108,324.60
	6/27/2025	Intercompany Funding	Portfolio Company	\$192,623.00
	7/1/2025	Intercompany Funding	Portfolio Company	\$650,000.00
	7/10/2025	Intercompany Funding	Portfolio Company	\$121,000.00
	7/18/2025	Intercompany Funding	Portfolio Company	\$118,000.00
	7/29/2025	Intercompany Funding	Portfolio Company	\$100,000.00
	8/14/2025	Intercompany Funding	Portfolio Company	\$250,000.00
	8/22/2025	Intercompany Funding	Portfolio Company	\$73,000.00
	10/3/2025	Intercompany Funding	Portfolio Company	\$9,307.50
	10/10/2025	Intercompany Funding	Portfolio Company	\$70,000.00
	10/28/2025	Intercompany Funding	Portfolio Company	\$105,000.00
	11/12/2025	Intercompany Funding	Portfolio Company	\$30,000.00
	11/19/2025	Intercompany Funding	Portfolio Company	\$5,285.00
	11/25/2025	Intercompany Funding	Portfolio Company	\$41,000.00
12/9/2025	Intercompany Funding	Portfolio Company	\$30,000.00	
			SUBTOTAL	\$8,303,540.10
Nine Square Therapeutics, Inc. 651 Gateway Blvd, Suite 1600 South San Francisco, CA 94080	1/31/2025	Intercompany Funding	Portfolio Company	\$4,000,000.00
	4/18/2025	Intercompany Funding	Portfolio Company	\$1,600,000.00
	7/30/2025	Intercompany Funding	Portfolio Company	\$200,000.00
	8/14/2025	Intercompany Funding	Portfolio Company	\$150,000.00
	9/18/2025	Intercompany Funding	Portfolio Company	\$90,000.00
	9/24/2025	Intercompany Funding	Portfolio Company	\$100,000.00
	10/10/2025	Intercompany Funding	Portfolio Company	\$55,000.00
	10/28/2025	Intercompany Funding	Portfolio Company	\$127,000.00
	11/3/2025	Intercompany Funding	Portfolio Company	\$20,270.00
	11/12/2025	Intercompany Funding	Portfolio Company	\$38,000.00
	11/19/2025	Intercompany Funding	Portfolio Company	\$8,510.00
	11/25/2025	Intercompany Funding	Portfolio Company	\$30,000.00
12/5/2025	Intercompany Funding	Portfolio Company	\$10,000.00	
12/9/2025	Intercompany Funding	Portfolio Company	\$38,000.00	
			SUBTOTAL	\$6,466,780.00
Red Queen Therapeutics, Inc. 245 Main Street 12th floor Cambridge, MA 02142	4/3/2025	Intercompany Funding	Portfolio Company	\$1,000,000.00
	12/9/2025	Intercompany Funding	Portfolio Company	\$16,000.00
				SUBTOTAL
Replicate Bioscience, Inc. 11558 Sorrento Valley Rd Ste 6 San Diego, CA 92121	1/10/2025	Intercompany Funding	Portfolio Company	\$1,250,000.00
	2/12/2025	Intercompany Funding	Portfolio Company	\$5,000,000.00

In re: ATP Life Science Ventures, L.P.**Case No. 25-12178**

SOFA 4 Attachment

Payments or other transfers of property made within 1 year before filing this case that benefited any insider

Creditor Name & Address	Payment Date	Reason for Payment	Relationship to Debtor	Amount Paid
Replicate Bioscience, Inc. (Continued)	7/11/2025	Intercompany Funding	Portfolio Company	\$2,500,000.00
	8/21/2025	Intercompany Funding	Portfolio Company	\$1,500,000.00
			SUBTOTAL	\$10,250,000.00
Seth L Harrison 230 Park Avenue, Suite 2800 New York, NY 10169	4/10/2025	Tax Distribution	Director	\$178,260.54
			SUBTOTAL	\$178,260.54

In re: ATP Life Science Ventures, L.P.

Case No. 25-12178

SOFA 11 Attachment

Payments related to bankruptcy

Creditor Name & Address	Email or Website	Who Made the Payment	If Not Money, Describe Property	Dates	Amount Paid
B Riley Financial/Securities 299 Park Ave New York, NY 10171	brileysecurities.com			12/09/2025	\$250,000.00
				SUBTOTAL	\$250,000.00
Potter Anderson & Corroon LLP PO Box 951 Wilmington, DE 19899-0951	potteranderson.com			12/03/2025	\$100,000.00
				SUBTOTAL	\$100,000.00
Quinn Emanuel Urquhart & Sullivan, LLP 865 S Figueroa Street, 10th Floor Los Angeles, CA 90017	quinnemanuel.com			12/09/2025	\$500,000.00
				SUBTOTAL	\$500,000.00
R&H Restructuring PO Box 897 Windward 1, Grand Cayman KY1-1103 Cayman Islands	rhrestructuring.com			11/24/2025	\$50,000.00
				SUBTOTAL	\$50,000.00

In re: ATP Life Science Ventures, L.P.

Case No. 25-12178

Attachment 25

Other businesses in which the debtor has or has had an interest

Business name	Address 1	Address 2	City	State	Zip	Country	Nature of business	Employer Identification number	Dates business existed
Adendra Therapeutics Limited	The Gridiron Building, Suite 6.05	1 Pancras Square	London		N1C 4AG	United Kingdom	Biotechnology Research		September 2021 - December 2023
Aethon Therapeutics, Inc.	760 Parkside Ave		New York	NY	11226		Biotechnology Research	88-4215231	November 2022 - Present
Akero Therapeutics, Inc.	601 Gateway Boulevard	Suite 350	South San Francisco	CA	94080		Biotechnology Research		March 2017 - June 2021
Apertor Pharmaceuticals, Inc.	651 Gateway Blvd, Suite 1600		South San Francisco	CA	94080		Biotechnology Research	85-3493161	November 2020 - Present
Apple Tree Life Sciences, Inc.	230 Park Avenue, Suite 2800		New York	NY	10169		Operating Company	45-1584506	April 2011 - Present
Ascidian Therapeutics, Inc.	80 Guest Street	4th Floor	Boston	MA	02135		Biotechnology Research		June 2021 - Present
ATP Research & Development, Inc.	230 Park Avenue, Suite 2800		New York	NY	10169		Biotechnology Research	85-2524766	August 2020 - Present
Aulos Bioscience, Inc.	700 Larkspur Landing Circle	Suite 108	Larkspur	CA	94939		Biotechnology Research	85-3272126	October 2020 - Present
Braeburn Inc	450Plymouth Rd	Suite 400	Plymouth Meeting	PA	19462		Biotechnology Research		July 2015 - Present
Deep Apple Therapeutics, Inc.	230 Park Avenue, Suite 2800		New York	NY	10169		Biotechnology Research	87-3668675	December 2021 - Present
Evercrisp Therapeutics, Inc.	651 Gateway Blvd, Suite 1600		South San Francisco	CA	94080		Biotechnology Research	87-1544437	August 2021 - Present
Galvanize Therapeutics, Inc.	3200 Bridge Parkway		Redwood City	CA	94065		Biotechnology Research	85-5112839	June 2021 - Present
Initial Therapeutics, Inc.	651 Gateway Blvd, Suite 1600		South San Francisco	CA	94080		Biotechnology Research	85-0692453	July 2020 - Present
Marengo Therapeutics, Inc.	840 Memorial Drive	4th Floor	Cambridge	MA	02139		Biotechnology Research	47-5622851	June 2021 - Present
Marlinspike Therapeutics, Inc.	245 Main Street	12th Floor	Cambridge	MA	02142		Biotechnology Research	87-4004757	February 2022 - Present
Nereid Therapeutics, Inc.	230 Park Avenue, Suite 2800		New York	NY	10169		Biotechnology Research	85-3368493	October 2020 - Present
Nine Square Therapeutics, Inc.	245 Main Street	12th Floor	Cambridge	MA	02142		Biotechnology Research	85-0634503	June 2020 - Present
Red Queen Therapeutics, Inc.	11558 Sorrento Valley Road	Suite 6	San Diego	CA	92121		Biotechnology Research	87-2028563	October 2021 - Present
Replicate Bioscience, Inc.	45 Wiggins Ave		Bedford	MA	01730		Biotechnology Research	96-1495974	February 2021 - Present
Stoke Therapeutics, Inc.	116 Huntington Ave	Suite 301	Boston	MA	02116		Biotechnology Research		July 2017 - June 2021
Syntimmune, Inc.	Fiveways, 57-59 Hatfield Road	Potter Bar, Hertsmere	Hertfordshire		EN6 1HS	United Kingdom	Biotechnology Research		October 2014 - November 2018

In re: ATP Life Science Ventures, L.P.

Case No. 25-12178

Attachment 28

Current Partners, Officers, Directors and Shareholders

Name	Address 1	Address 2	City	State	Zip	Country	Position and nature of any interest	% of interest, if any	Fund
Anna Batarina	40 Grove End Road		London		NW8 9NE	United Kingdom	Equity Holder	1.20%	Pool ATP IV
Les Pommès	230 Park Avenue, Suite 2800		New York	NY	10169		Equity Holder	0.75%	Pool ATP IV
Les Pommès	230 Park Avenue, Suite 2800		New York	NY	10169		Equity Holder	0.84%	Pool ATP IV
Les Pommès	230 Park Avenue, Suite 2800		New York	NY	10169		Equity Holder	0.51%	Pool V-3
Rigmora Biotech Investor One LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	47.20%	Pool ATP IV
Rigmora Biotech Investor One LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	41.80%	Pool ATP IV
Rigmora Biotech Investor One LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	49.00%	Pool Braeburn
Rigmora Biotech Investor One LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	49.00%	Pool V-1
Rigmora Biotech Investor One LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	49.00%	Pool V-2
Rigmora Biotech Investor One LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	48.04%	Pool V-3
Rigmora Biotech Investor Two LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	49.13%	Pool ATP IV
Rigmora Biotech Investor Two LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	43.70%	Pool ATP IV
Rigmora Biotech Investor Two LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	51.00%	Pool Braeburn
Rigmora Biotech Investor Two LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	51.00%	Pool V-1
Rigmora Biotech Investor Two LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	51.00%	Pool V-2
Rigmora Biotech Investor Two LP	3076, Sir Francis Drakes Highway	Road Town	Tortola			BVI	Equity Holder	51.00%	Pool V-3
Seth L. Harrison, MD.	230 Park Avenue, Suite 2800		New York	NY	10169		Equity Holder	0.67%	Pool ATP IV
Seth L. Harrison, MD.	230 Park Avenue, Suite 2800		New York	NY	10169		Equity Holder	0.74%	Pool ATP IV
Seth L. Harrison, MD.	230 Park Avenue, Suite 2800		New York	NY	10169		Equity Holder	0.45%	Pool V-3
Seth L. Harrison, MD.	230 Park Avenue, Suite 2800		New York	NY	10169		General Partner	0.00%	